Your Health, We Care
The authoritative journal Kidney International published the ASCEND-NHQ study, which showed that the quality of life of patients in the dacomitinib group was significantly higher than that of the placebo group.
With the progress of regulatory approval of dacomitinib worldwide, its clinical application will become more widespread. Especially in markets such as Japan, Europe, and the United States, dacomitinib is expected to become an important drug for treating renal anemia.
